Want to see SE:FLERIE full AI Analyst Report?

InDex Pharmaceuticals Holding AB (FLERIE) Price & Analysis

2 Followers

FLERIE Stock Chart & Stats

kr20.40

-kr0.20(-0.98%)

At close: Jul 28 4:00 PM EDT

kr20.40

-kr0.20(-0.98%)

Day’s Range― - ―

52-Week Rangekr19.40 - kr39.86

Previous CloseN/A

Volume46.31K

Average Volume (3M)10.31K

Market Cap

kr1.87B

Enterprise Valuekr1.53K

Total Cash (Recent Filing)kr305.70M

Total Debt (Recent Filing)kr1.70M

Price to Earnings (P/E)―

Beta0.12

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.56

Shares Outstanding86,697,700

10 Day Avg. Volume8,358

30 Day Avg. Volume10,307

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)0.76

Price to Sales (P/S)290.28

P/FCF Ratio-90.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetExtremely low debt relative to equity materially reduces refinancing and solvency risk, providing structural financial flexibility. For a clinical-stage biotech this supports funding trials, negotiating partner deals, and surviving R&D cycles over the next several months.

Focused Pipeline (cobitolimod)A clear product focus on cobitolimod and immunology gives a defined development path and addressable indication. Concentrated R&D resources raise the probability of producing a partnerable asset or licensing transaction, a durable monetization route for clinical-stage firms.

Improving Free Cash Flow TrendYear‑over‑year improvement in free cash flow indicates operational or timing gains that reduce net burn. If sustained, this trend lengthens runway, lowers near‑term financing reliance, and improves the company’s ability to advance trials or negotiate partnerships.

Bears Say

Large Persistent LossesVery large and persistent net losses show the cost base far exceeds revenue. Structural unprofitability erodes equity, constrains the company’s ability to self‑fund development, and weakens negotiating leverage with potential partners or future investors.

Negative Operating Cash Flow / Cash BurnMeaningful negative operating and free cash flow reflect ongoing cash burn and reliance on external funding. This raises dilution and execution risk for multi‑stage clinical programs and forces prioritization of projects or urgent financing needs within months.

Volatile, Negative Revenue And No Commercial SalesRevenue volatility and a negative TTM top line, combined with clinical‑stage status and no recurring commercial product revenue, reduce visibility into future cash flows. Dependence on licensing, milestones, or fundraising increases execution risk and planning uncertainty.

FLERIE FAQ

What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?

InDex Pharmaceuticals Holding AB lowest stock price was kr19.40 and its highest was kr39.86 in the past 12 months.

What is InDex Pharmaceuticals Holding AB’s market cap?

InDex Pharmaceuticals Holding AB’s market cap is kr1.87B.

When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?

InDex Pharmaceuticals Holding AB’s upcoming earnings report date is Oct 15, 2026 which is in 74 days.

How were InDex Pharmaceuticals Holding AB’s earnings last quarter?

InDex Pharmaceuticals Holding AB released its earnings results on Jul 09, 2026. The company reported -kr1.017 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.017.

Is InDex Pharmaceuticals Holding AB overvalued?

According to Wall Street analysts InDex Pharmaceuticals Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InDex Pharmaceuticals Holding AB pay dividends?

InDex Pharmaceuticals Holding AB does not currently pay dividends.

What is InDex Pharmaceuticals Holding AB’s EPS estimate?

InDex Pharmaceuticals Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InDex Pharmaceuticals Holding AB have?

InDex Pharmaceuticals Holding AB has 86,697,700 shares outstanding.

What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?

InDex Pharmaceuticals Holding AB reported an EPS of -kr1.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?

Currently, no hedge funds are holding shares in SE:FLERIE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InDex Pharmaceuticals Holding AB

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.